Allovir, Inc. (ALVR) is trading 13% higher at $5.23 today.

Allovir, Inc. has been trading between a 52-week high of $26.41 and a 52-week low of $3.17. The stock has a market cap of $342 Million.

AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy.

AlloVir stock surges on $126.6M securities offering (NASDAQ:ALVR)
Seeking Alpha 07-27-22

Thinking Of Selling AlloVir Inc. (NASDAQ: ALVR) Shares? You Need To Know This
Stocks Register 06-18-22

AlloVir''s Posoleucel Shows Early Safety In Kidney Transplant Recipients
Benzinga 06-07-22

AlloVir''s phase 2 posoleucel study shows BK viral load decline in kidney transplant patients
Seeking Alpha 06-07-22

AlloVir GAAP EPS of -$0.69 beats by $0.11
Seeking Alpha 05-05-22